Cancer Communications
indexed by SCI
BMC

doi: 10.1186/s40880-017-0193-8
Corepressor metastasis-associated protein 3 modulates epithelial-to-mesenchymal transition and metastasis
Liang Du, Zhifeng Ning, Fuxing Liu and Hao Zhang
Cancer Research Center, Shantou University Medical College
[Abstract] Worldwide, metastasis is the leading cause of more than 90% of cancer-related deaths. Currently, no specific therapies effectively impede metastasis. Metastatic processes are controlled by complex regulatory networks and transcriptional hierarchy. Corepressor metastasis-associated protein 3 (MTA3) has been confirmed as a novel component of nucleosome remodeling and histone deacetylation (NuRD). Increasing evidence supports the theory that, in the recruitment of transcription factors, coregulators function as master regulators rather than passive passengers. As a master regulator, MTA3 governs the target selection for NuRD and functions as a transcriptional repressor. MTA3 dysregulation is associated with tumor progression, invasion, and metastasis in various cancers. MTA3 is also a key regulator of E-cadherin expression and epithelial-to-mesenchymal transition. Elucidating the functions of MTA3 might help to find additional therapeutic approaches for targeting components of NuRD.
Chinese Journal of Cancer 2017, Volume: 36, Issue 3
[ PDF Full-text ]
[ Html full-text / Citation export] (BioMed Central)

[Google Scholar]


Cite this article

Liang Du, Zhifeng Ning, Fuxing Liu and Hao Zhang. Corepressor metastasis-associated protein 3 modulates epithelial-to-mesenchymal transition and metastasis. Chin J Cancer. 2017, 36:28. doi:10.1186/s40880-017-0193-8


Export citations

EndNote


SHARE THIS ARTICLE


Your Comments

  

 


Comments:


CJC Wechat 微信公众号


 

Editorial Manager


CC adopts ScholarOne Manuscripts to manage its submissions from Nov.1, 2019

 Submission Guidelines  

 

Reference style for  

 EndNote,
 Reference Manager



Editorial Manager


 

Year:

 

Month:

Advanced search

Subscription


CC is now published by Wiley

© Cancer Communications

651 Dongfeng Road East, Guangzhou 510060, P. R. China